A team from the National University of Medical Sciences (NUMS) Office of Research Innovation and Commercialization (ORIC) visited Solaris Life Sciences (Pvt.) Ltd. located in the Industrial Estate Rawat, Rawalpindi.Discussions with Solaris' management provided insights into their operations and future prospects. Dr. Bakht Zaman from Solaris expressed interest in joint research, internships, and capacity-building initiatives. This visit sets the stage for a promising partnership between NUMS and Solaris.

On January 16, 2024, a delegation from PharmEvo (Pvt). Ltd. Karachi, Pakistan, embarked on a collaborative visit to the National University of Medical Sciences (NUMS), marking a significant stride in fostering partnerships between academia and industry. The esteemed delegation, led by the NUMS Office of Research, Innovation, and Commercialization (ORIC), comprised the following distinguished members:

1. Dr.Shahid Waseem, Director ORIC
2. Mr. Zahoor Khan, Assistant Director Industrial Linkages

The PharmEvo (Pvt). Ltd. Karachi, Pakistan delegation featured notable figures, including:

1. Dr. Masood Jawaid Director Medical Affairs
2. Mr. Shahid Khan HOD NTL/BUH

The visit's agenda was diverse, encompassing an illuminating presentation by the Director of the Office of Research, Innovation, and Commercialization (ORIC), highlighting NUMS' research capabilities and current projects. Subsequent conversations explored potential collaborations in research and development, with insights from the PharmEvo Pvt Ltd team on their groundbreaking initiatives. The ORIC team outlined NUMS' strategic approach to fostering industrial linkages, underscoring the mutual advantages of joint projects. A comprehensive tour of NUMS facilities, tailored to the delegation's interests, provided a firsthand glimpse into the university's state-of-the-art infrastructure. The visit concluded with an informal networking session, during which both parties affirmed their shared commitment to exploring future collaborations. As evidence of the positive rapport established, ongoing discussions aim to formalize potential partnerships and delineate the scope of collaborative projects. This signifies a dynamic and capable collaboration between PharmEvo Pvt Ltd and NUMS, dedicated to advancing medical research, capacity building, and innovation in a new paradigm.

On December 29, 2023, a delegation from Hamdard Laboratories (Waqf) Karachi, Pakistan, embarked on a collaborative visit to the National University of Medical Sciences (NUMS), marking a significant stride in fostering partnerships between academia and industry. The esteemed delegation, led by the NUMS Office of Research, Innovation, and Commercialization (ORIC), comprised the following distinguished members:

1. Dr.Shahid Waseem, Director ORIC
2. Mr. Amjid Mehmood, Deputy Director Marketing & Business Development
3. Mr. Zahoor Khan, Assistant Director of Industrial Linkages

The Hamdard Laboratories (Waqf) Pakistan delegation featured notable figures, including:

1. Hakeem Abdul Bari, Head of HRC
2. Prof Dr. Syed Faisal Haider, Associate Dean Faculty of Eastern Medicine
3. Mr. Shahzad Afzal Kayani, Director QEC

The agenda for the visit was multifaceted, incorporating an enlightening demonstration by the Director of ORIC, showcasing NUMS' research capabilities and ongoing projects. Subsequent discussions delved into potential collaborations in research and development, with the Hamdard team providing insights into their pioneering initiatives. The ORIC team presented NUMS' strategic approach to industrial linkages, emphasizing the mutual benefits of collaborative projects.

A comprehensive tour of NUMS facilities, tailored to the delegation's interests, offered a firsthand look at the university's cutting-edge infrastructure. The visit concluded with an informal networking session, during which both parties expressed a shared commitment to exploring future collaborations.

As a testament to the positive rapport established, ongoing discussions are set to formalize potential partnerships and define the scope of collaborative projects. This reflects a robust and capable cooperation between Hamdard Laboratories and NUMS in advancing medical research and innovation.

DoU signed: December 4, 2023

Purpose of Collaboration:

The purpose of this DoU is to create and establish a formal mutually beneficial working relationship between Qarshi Research International (Pvt.) Ltd and NUMS.

Scope of Collaboration:

1. To promote research and development by collaborating in the following areas;
   • Herbal products developments
   • Quality control of herbal products
   • Active Pharmaceutical Ingredients (APIs),
   • Chemical Marker Identification and Qualification in plant Materials and Qarshi Products,
   • Plant cell culturing
   • Clinical trials of Qarshi products
   • Conduct research at Qarshi and sharing of expertise and resources with each other.

DoU signed: August 10, 2022

Scope of Collaboration:

1.  To promote cooperation in the areas of education, research and capacity building.
2.  To build the capacity and strengthening the efficacy and effectiveness of members of rural communities and professionals for unlocking their true human, social and economic potential.

MOU signed: Friday, 22nd January, 2021

Scope of Collaboration:

1.  To strengthen research cooperation in the development of medical sciences. 
2.  To facilitate exchange of faculties, scientists and experts for joint research project.
3.  To promote and achieve excellence in advanced health education, research and service delivery to eventually run the university health care system. 

MOU signed: Wednesday, March 17, 2021

Scope of Collaboration:

1.  To exchange information, compliance, training and capacity building in view of the university’s plans revolving around Bioequivalence and Clinical Trials involving human subjects.
2.  To lay foundation for research and quality products in the country.

DOU signed: June 18, 2021

Scope of Collaboration:

1.  enhance cooperation in the field of research and development pertaining to healthcare.
2.  building and training with special emphasis on pharmaceutical testing including bioequivalence studies, clinical trials and healthcare products development.
3.  To seek opportunities to contribute to clinical research, product, and capacity development of key stakeholders.

DOU signed: November 24, 2021

Scope of Collaboration:

1.  To promote and achieve expertise in advanced health education, research and service delivery.
2.  To ensure research and development pertaining to healthcare including capacity building and training with special emphasis on pharmaceutical testing including bioequivalence studies, clinical trials and healthcare products development.

DOU signed: October 6, 2017

Scope of Collaboration:

1.  Academic Collaboration to deliver higher education effectively. 
2.  Joint research and development projects.
3.  Academic cooperation, collaborative seminars, workshops and training courses.

MOU signed: March 7, 2019

Scope of Collaboration:

1.  Exchange of Examiners, Guest Speakers -Subject Experts. 
2.  Joint Workshops/ Seminars on Medical Education and Research

MOU signed: March 14, 2017

Scope of Collaboration:

1.  Research and development projects. 
2.  Exchange of technical expertise,
3.  Collaborative seminars, workshops and training courses

MOU signed: June 09, 2016

Scope of Collaboration:

1.  Cooperation in Academics and Research . 

DOU Signed: Dec 03, 2019

Scope of Collaboration:

1.  Pursuance of collaborative research projects in Biosciences as well as other disciplines. 
2.  Initiation of faculty/student exchange programs. 

Scope of Collaboration:

1.  Health care surveillance. 
2.  Initiation of research projects and faculty/student exchange programs . 

MOU Signed: April 29, 2019

Scope of Collaboration:

1.  Student and administrative/academic staff exchange. 
2.  Joint research activities
3.  Sharing of publication/reports etc.

DOU Signed: Dec 06, 2019

Scope of Collaboration:

1.  Exchange of faculty – short or long time. 
2.  Student exchange - short or long time. 
3.  Collaborative research. 

DOU signed on: April 20, 2021

Scope of Collaboration:

1.  To develop and execute north development clinical development activities.
2.  Conduction of bioavailability / bioequivalence clinical trials.

LOI signed: June 23, 2021

Scope of Collaboration:

1.  To develop joint activities and programs for exchange of academic faculty, research personnel, research fellows between the institutions for research and study.
2.  To cooperate and collaborate in the broad field of medical research.